Novel approaches in anaplastic thyroid cancer therapy

Oncologist

Volumn 19, Issue 11, 2014, Pages 1148-1155

  Hsu, Kun Tai ^a   Yu, Xiao Min ^a   Udhya, Anjon W A ^a   Jaume, Juan C ^a   Loyd, Ricardo V L ^a   Miyamoto, Shigeki ^a   Prolla, Tomas A ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Anaplastic thyroid cancer; Clinical trials; Histone deacetylase inhibitors; Kinase inhibitors; Notch; Thyroid cancer

Indexed keywords

AXITINIB; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; JAGGED2; MEMBRANE PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE KINASE A; RAS PROTEIN; SODIUM IODIDE SYMPORTER; SORAFENIB; THROMBOPOIETIN; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; NOTCH1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RET PROTEIN, HUMAN; TUMOR MARKER;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; IMMUNOMODULATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; GENE THERAPY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; THYROID CARCINOMA, ANAPLASTIC;

BIOMARKERS, TUMOR; GENETIC THERAPY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RAF KINASES; RAS PROTEINS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC;

EID: 84908508724     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0182     Document Type: Article

References (144)

1. Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 1998;83:2638–2648.
2. Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors. Cancer 2005;103:1330–1335.
3. Are C, Shaha AR. Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453–464.
4. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501–511.
5. Neff RL, Farrar WB, Kloos RT et al. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525–538, xi.
6. Chen J, Tward JD, Shrieve DC et al. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: Analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008;31:460–464.
7. O’Neill JP, Shaha AR. Anaplastic thyroid cancer. Oral Oncol 2013;49:702–706.
8. Smallridge RC, Ain KB, Asa SL et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:1104–1139.
9. Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag 2008;4:935–947.
10. Spitzweg C, Harrington KJ, Pinke LA et al. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001;86:3327–3335.
11. Spitzweg C. Gene therapy in thyroid cancer. Horm Metab Res 2009;41:500–509.
12. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010;22:486–497.
13. Deshpande HA, Roman S, Sosa JA. New targeted therapies and other advances in the management of anaplastic thyroid cancer. Curr Opin Oncol 2013;25:44–49.
14. Park JW, Clark OH. Redifferentiation therapy for thyroid cancer. Surg Clin North Am 2004;84: 921–943.
15. Spitzweg C, Morris JC. The sodium iodide symporter: Its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 2002;57:559–574.
16. Dohán O, De la Vieja A, Paroder V et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003;24:48–77.
17. Ferretti E, Tosi E, Po A et al. Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab 2008;93:4080–4087.
18. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neu-roendocrinephenotypeofmedullary thyroidcancer cells. J Biol Chem 2006;281:39819–39830.
19. Moore JH Jr., Bacharach B, Choi HY. Anaplastic transformation of metastatic follicular carcinoma of the thyroid. J Surg Oncol 1985;29:216–221.
20. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev 1994;15:202–232.
21. Santoro M, Carlomagno F, Hay ID et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992;89:1517–1522.
22. Ruco LP, Ranalli T, Marzullo A et al. Expression of Met protein in thyroid tumours. J Pathol 1996; 180:266–270.
23. Bongarzone I, Pierotti MA, Monzini N et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457–1462.
24. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000;289:1357–1360.
25. Fagin JA, Matsuo K, Karmakar A et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–184.
26. Jossart GH, Epstein HD, Shaver JK et al. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. JClin Endocrinol Metab 1996;81:3498–3504.
27. Moretti F, Nanni S, Farsetti A et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 2000;85:302–308.
28. Ros P, Rossi DL, Acebrón A et al. Thyroid-specific gene expressioninthe multi-step process of thyroid carcinogenesis. Biochimie 1999;81:389–396.
29. Russo D, Bulotta S, Bruno R et al. Sodium/ iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 2001;145: 591–597.
30. Mian C, Lacroix L, Alzieu L et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001;11:825–830.
31. Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010;95:820–828.
32. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581–588.
33. Kimura ET, Nikiforova MN, Zhu Z et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res2003;63:1454–1457.
34. Romei C, Elisei R. Ret/ptc translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (Lausanne) 2012;3:54.
35. Gupta N, Dasyam AK, Carty SE et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab 2013;98: E914–E922.
36. Garcia-Rostan G, Zhao H, Camp RL et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226–3235.
37. Lemoine NR, Mayall ES, Wyllie FS et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4: 159–164.
38. Basolo F, Pisaturo F, Pollina LE et al. N-ras mutation in poorly differentiated thyroid carcinomas: Correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000;10:19–23.
39. Saavedra HI, Knauf JA, Shirokawa JM et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000; 19:3948–3954.
40. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. The Oncologist 2013;18:926–932.
41. Mitsutake N, Knauf JA, Mitsutake S et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465–2473.
42. Puxeddu E, Durante C, Avenia N et al. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008;19:138–145.
43. Liu D, Hu S, Hou P et al. Suppression of BRAF/ MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007; 13:1341–1349.
44. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69: 8317–8325.
45. Romei C, Ciampi R, Faviana P et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyro-peroxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008; 15:511–520.
46. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na1/I- targeting to the membrane. Endocr Relat Cancer 2006;13:257–269.
47. Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade medi-atesthe motile and mitogenic phenotypeofthyroid cancer cells. J Clin Invest 2005;115:1068–1081.
48. Mesa C Jr., Mirza M, Mitsutake N et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006; 66:6521–6529.
49. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245–262.
50. Granata R, Locati L, Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: Review of the current literature. Curr Opin Oncol 2013;25:224–228.
51. Greco A, Mariani C, Miranda C et al. The DNA rearrangementthatgeneratestheTRK-T3oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 1995;15:6118–6127.
52. Hernández L, Pinyol M, Hernández S et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265–3268.
53. Hernández L, Beà S, Bellosillo B et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: Identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002;160:1487-1494.
54. Roccato E, Miranda C, Raho G et al. Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein. J Biol Chem 2005; 280:3382-3389.
55. Witte K, Schuh AL, Hegermann J et al. TFG-1 function in protein secretion and oncogenesis. Nat Cell Biol 2011;13:550-558.
56. Bolos V, Grego-Bessa J, de la Pompa JL Notch signaling in development and cancer. Endocr Rev 2007;28:339-363.
57. Radtke F, Raj K. The role of Notch in tumor-igenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-767.
58. Nickoloff BJ, Qin JZ, Chaturvedi V et al. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappa Band PPAR gamma.Cell Death Differ 2002;9: 842-855.
59. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 2005;90: 4350-4356.
60. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastro-intest Liver Physiol 2005;289:G636-G642.
61. Shou J, Ross S, Koeppen H et al. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001;61: 7291-7297.
62. Talora C, Sgroi DC, Crum CP et al. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002;16:2252-2263.
63. Yu XM, Jaskula-Sztul R, Ahmed K et al. Resver-atrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther 2013;12:1276-1287.
64. Carre A, Rachdi L, Tron E et al. Hes1 is required for appropriate morphogenesis and differentiation during mouse thyroid gland development. PLoS One 2011;6:e16752.
65. Hong L, Schroth GP, Matthews HR et al. Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 “tail” to DNA. J Biol Chem 1993;268: 305-314.
66. Nagy L, Kao HY, Chakravarti D et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histonedeacetylase. Cell 1997;89:373-380.
67. Kitazono M, Robey R, Zhan Z et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of theNa(+)/I(—)symporterand iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:3430-3435.
68. Furuya F, Shimura H, Suzuki H et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorlydifferentiated and anaplastic thyroid cancer cells by expression of the sodium/ iodide symporter thyroperoxidase and thyroglobu-lin. Endocrinology 2004;145:2865-2875.
69. Puppin C, D’Aurizio F, D’Elia AV et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005;146:3967–3974.
70. Zhang Z, Liu D, Murugan AK et al. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 2014;21:161–173.
71. Miyamoto S. Nuclear initiated NF-kBsignaling: NEMO and ATM take centerstage. Cell Res 2011;21: 116–130.
72. Pacifico F, Leonardi A. Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 2010;321: 29–35.
73. Meng Z, Lou S, Tan J et al. Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I. PLoS One 2012; 7:e33597.
74. Meng Z, Lou S, Tan J et al. Nuclear factor-kappa B inhibition can enhance therapeutic efficacyof131I ontheinvivo managementofdifferentiated thyroid cancer. Life Sci 2012;91:1236–1241.
75. Gallel P, Pallares J, Dolcet X et al. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Hum Pathol 2008;39:994–1001.
76. Neely RJ, Brose MS, Gray CM et al. The RET/ PTC3 oncogene activates classical NF-kB by stabilizing NIK. Oncogene 2011;30:87–96.
77. Liu J, Brown RE. Morphoproteomic confirma-tionofanactivated nuclear factor-Bp65 pathway in follicular thyroid carcinoma. Int J Clin Exp Pathol 2012;5:216–223.
78. Volpe V, Raia Z, Sanguigno L et al. NGALcontrols the metastatic potential of anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2013;98:228–235.
79. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883–899.
80. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441: 431–436.
81. Kapiteijn E, Schneider TC, Morreau H et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012;23:10–18.
82. Kogan EA, Rozhkova EB, Seredin VP et al. [Prognostic value of the expression of thyreoglobu-lin and oncomarkers (p53, EGFR, ret-oncogene) in different typesofpapillary carcinomaof the thyroid: Clinicomorphological and immunohistochemical studies]. Arkh Patol 2006;68:8–11.
83. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317–323.
84. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacoki-netic and clinical results. J Clin Oncol 2005;23: 5474–5483.
85. Cohen EE, Rosen LS, Vokes EE et al. Axitinibisan active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708–4713.
86. Salvatore G, De Falco V, Salerno P et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623–1629.
87. Ouyang B, Knauf JA, Smith EP et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006;12:1785–1793.
88. Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785–1792.
89. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–4719.
90. Brose MS, Nutting C, Jarzab B et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III decision trial. A. J Clin Oncol 2013; XXX(suppl):31.
91. Savvides P, Nagaiah G, Lavertu P et al. Phase II trial of sorafenib in patients with advanced anaplas-tic carcinoma of the thyroid. Thyroid 2013;23: 600–604.
92. U.S. National Institutes of Health. NCT01013597. http://www.clinicaltrials.gov. Accessed March 7, 2014.
93. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194–202.
94. Phiel CJ, Zhang F, Huang EY et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and terato-gen. J Biol Chem 2001;276:36734–36741.
95. Catalano MG, Poli R, Pugliese M et al. Valproic acid enhances tubulin acetylation and apoptotic activityofpaclitaxelonanaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007;14:839–845.
96. Catalano MG, Pugliese M, Poli R et al. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol Rep 2009;21:515–521.
97. Fortunati N, Catalano MG, Arena K et al. Valproic acid induces the expression of the Na1/I-symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004;89:1006–1009.
98. Lee WW, Lee B, Kim SJ et al. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol Rep 2003;10: 845–849.
99. Haberkorn U, Beuter P, Kübler W et al. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter genein rat thyroid carcinoma cells. J Nucl Med 2004;45:827–833.
100. Furuya F, Shimura H, Miyazaki A et al. Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 2004;145:5397–5405.
101. Elisei R, Vivaldi A, Ciampi R et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 2006;91:2389–2395.
102. Petrich T, Helmeke HJ, Meyer GJ et al. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29:842–854.
103. Barzon L, Bonaguro R, Castagliuolo I et al. Gene therapy of thyroid cancer via retrovirally-drivencombined expressionofhuman interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 2003;148:73–80.
104. Barzon L, Gnatta E, Castagliuolo I et al. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. Cancer Gene Ther 2005;12:381–388.
105. Lee YJ, Chung JK, Kang JH et al. Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplasticthyroidcancermodel. EurJNuclMedMol Imaging 2010;37:235–241.
106. Moretti F, Farsetti A, Soddu S et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997;14:729–740.
107. Yu XM, Phan T, Patel PN et al. Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer 2013;119:774–781.
108. Kang HJ, Youn YK, Hong MK et al. Antiprolif-eration and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals. J Korean Med Sci 2011;26:893–899.
109. Richardson PG, Mitsiades C, Hideshima T et al. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57:33–47.
110. Hideshima T, Mitsiades C, Tonon G et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585–598.
111. Putzer D, Gabriel M, Kroiss A et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 2012;37:539–544.
112. Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006;91:4013–4021.
113. Starenki DV, Namba H, Saenko VA et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappa B inhibitor, dehydroxymethy-lepoxyquinomicin. Clin Cancer Res 2004;10:682–6829.
114. Starenki D, Namba H, Saenko V et al. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004;89:410–418.
115. Pacifico F, Mauro C, Barone C et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 2004;279:54610–54619.
116. Iannetti A, Pacifico F, Acquaviva R et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. ProcNatl AcadSciUSA 2008; 105:14058–14063.
117. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 2010;9:117.
118. Cras A, Politis B, Balitrand N et al. Bexarotene via CBP/p300 induces suppression of NF-kB-dependent cell growth and invasion in thyroid cancer. Clin Cancer Res 2012;18:442–453.
119. Rosato RR, Kolla SS, Hock SK et al. Histone deacetylaseinhibitors activateNF-kappaBinhuman leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010;285:10064–10077.
120. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004;5:419–429.
121. Park JW, Zarnegar R, Kanauchi H et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005;15:222–231.
122. Fröhlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyro-cytes in culture. Endocr Relat Cancer 2005;12: 291–303.
123. Antonelli A, Ferrari SM, Fallahi P et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endo-crinol (Oxf) 2009;70:946–953.
124. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301–1307.
125. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust. Drugs 2001;61:197–206.
126. Eisenberg DA. Cholesterol lowering in the managementofcoronaryarterydisease:Theclinical implications of recent trials. Am J Med 1998;104: 2S–5S.
127. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–1009.
128. Zhong WB, Wang CY, Chang TC et al. Lova-statin induces apoptosisofanaplastic thyroid cancer cells via inhibition of protein geranylgeranylation anddenovo protein synthesis. Endocrinology 2003; 144:3852–3859.
129. Di Matola T, D’Ascoli F, Luongo C et al. Lovastatin-induced apoptosis in thyroid cells: Involvement of cytochrome c and lamin B. Eur J Endocrinol 2001;145:645–650.
130. Wang CY, Zhong WB, Chang TC et al. Lovastatin, a 3-hydroxy-3-methylglutaryl coen-zyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003;88: 3021–3026.
131. Zhong WB, Liang YC, Wang CY et al. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCKsignaling. Endocr Relat Cancer 2005;12: 615–629.
132. Wang CY, Shui HA, Chang TC. Invivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer 2010;126:578–582.
133. Bifulco M, Laezza C, Aloj SM. Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. Biochimie 1999;81:287–290.
134. Takano T. Fetal cell carcinogenesis of the thyroid: Theory and practice. Semin Cancer Biol 2007;17:233–240.
135. Todaro M, Iovino F, Eterno V et al. Tumori-genic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010;70:8874–8885.
136. Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol 2013;44:1707–1713.
137. Lloyd RV, Hardin H, Montemayor-Garcia C et al. Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol 2013;24:1–10.
138. Buehler D, Hardin H, Shan W et al. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 2013;26:54-61.
139. Takano T. Fetal cell carcinogenesis of the thyroid: A modified theory based on recent evidence. EndocrJ 2014;61:311-320.
140. Montemayor-Garcia C, Hardin H, Guo Z et al. The role of epithelial mesenchymal transition markers in thyroid carcinoma progression. Endocr Pathol 2013;24:206-212.
141. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing theTcell response. Nat Rev Immunol 2012;12:269-281.
142. Paparodis R, Imam S, Todorova-Koteva K et al. Hashimoto’s thyroiditis pathology and risk for thyroid cancer. Thyroid 2014;24:1107-1114.
143. Imam S, Paparodis R, Sharma D et al. Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocr Relat Cancer 2014;21:505-516.
144. Foote RL, Molina JR, Kasperbauer JL et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: A single-institution experience usingaggressive multimodal therapy. Thyroid 2011;21:25-30.